In Vitro Diagnostics Companies

The in vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6 % from 2025 to 2030.

IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. The term "in vitro," which refers to "in glass," signifies that test tubes or petri dishes are typically used in these tests. These tests are performed artificially on biological samples (blood, urine, and tissues). IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits. IVD is used to assess a person's health. This technique is used in precision medicine to determine the suitable course of treatment for particular patients and diagnose and prevent diseases and other medical disorders.

To know about the assumptions considered for the study download the pdf brochure

The major factors driving the market growth of the in vitro diagnostics market include the increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, the emergence of rapid PoC technologies, rising adoption of automated analyzers, and growing preference for personalized medicines.

The market players have adopted various strategies, such as the development of advanced products, agreements, and expansions, to strengthen their position in the in vitro diagnostics market. In July 2024, Danaher (US) launched the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system that enhances patient care for hospitals and healthcare networks. In February 2025, F. Hoffmann-La Roche Ltd (Switzerland) unveiled a new category of next-generation sequencing (NGS) driven by its exclusive Sequencing by Expansion (SBX) technology, designed to improve the accuracy, efficiency, and scalability of sequencing. In November 2024, Siemens Healthineers AG (Germany) collaborated with the Ohio State Wexner Medical Center (US) to promote progress in medical treatment, enhancing their current research partnership.

Some of the prominent players operating in the market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMérieux (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Netherlands), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation (US), among others.

Market Ranking

The ranking of firms in the in vitro diagnostics market is based on market share analysis, secondary research, and validation from primary respondents. This rating takes into account revenue derived from product portfolio breadth and depth, innovation, and approvals/launches. The analysis reveals Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific Inc. (US) as the top five players guiding the market. These companies dominate because of their great market presence, a wide range of products, and ongoing in vitro diagnostics industry innovation.

F. Hoffmann-La Roche Ltd (Switzerland)

Roche is a global pioneer in IVD focused on developing novel products with advanced research capabilities. The combined strengths of diagnostics & automation and growing expertise in personalized healthcare help the company acquire a prominent market share. The differentiated product portfolio in infectious diseases, tissue diagnostics, oncology, and diabetes management makes the company a leading player in the IVD market. In November 2024, the company acquired Poseida Therapeutics, Inc. (US), a publicly traded clinical-stage biopharmaceutical company specializing in donor-derived CAR-T cell therapies.

Danaher (US)

Danaher has a broad product portfolio in segments like Biotechnology, Life Sciences, and Diagnostics. The company markets its IVD products in over 100 markets directly or indirectly. The Diagnostics segment provides clinical tools, consumables, reagents, software, and services required for illness diagnosis and treatment planning. One of the main pillars of the company's success is its vast global network of about 242 manufacturing and distribution sites. Danaher (US) keeps growing its diagnostics business through smart acquisitions and improvements in regulations. The purchase of Abcam plc (UK) on December 6, 2023, for about USD 5.6 billion, was a significant strategic decision that improved the capacity of the company in diagnostics and life sciences.

Abbott (US)

Abbott is a leading player in the IVD market with its commercial presence in 95 countries. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets. It holds a significant market share in the IVD sector due to its extensive range of products and approved items from the FDA and CE. The Alinity m MPXV Test, developed by Abbott (US) in October 2024, received emergency use authorization from the World Health Organization (WHO), becoming the first authorized diagnostic test for mpox. This accreditation significantly enhances the ability to diagnose, especially in countries experiencing Mpox outbreaks where swift and precise testing is crucial.

Siemens Healthineers AG (Germany)

The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Diagnostic segment deals with in vitro diagnostic products, services, and solutions. The company sells its products to healthcare providers in more than 180 countries. The company significantly invests in R&D to launch innovative and technologically advanced products. In line with this, in 2024, the company invested USD 2,107.7 million of its revenue in R&D activities. It has major R&D facilities in Germany, the US, China, and India.

Thermo Fisher Scientific Inc. (US)

The Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments, and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Thermo Fisher Scientific Inc. has undertaken pivotal developments to strengthen its offering in the diagnostics industry. For instance, to support customers in China and the Asia Pacific region, the company opened a new biologics manufacturing facility in Hangzhou, China, which provides integrated clinical and commercial drug substance and drug product capabilities.

Related Reports:

In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com